"Pharma R&D set to endure despite rising MFN costs" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

Advanced biotech equipment, driven by R&D investment and personalized medicine, is essential for scalable drug production and development into the next decade, according to a BCC Research report.

It’s becoming increasingly clear that pharmaceutical companies can live with President Trump’s tariffs. What the industry can’t live with is uncertainty on drug prices. The sector has long traded at a ...

India’s ₹5,000-cr plan opens applications to fund pharma and medtech R&D, helping firms move beyond low-cost generics toward ...

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as ...

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a ...